Press Releases

Date Title and Summary View
November 4, 2016 Eleven Biotherapeutics to Report Third Quarter 2016 Financial Results on November 14, 2016 View HTML
September 21, 2016 Eleven Biotherapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635©(4) View HTML
September 21, 2016 Eleven Biotherapeutics Acquires Viventia Bio to Create Targeted Protein Therapeutics Oncology Company View HTML
August 16, 2016 Eleven Biotherapeutics Completes Exclusive Licensing Deal for IL-6 Antagonist Antibody Technology, Including EBI-031 View HTML
August 12, 2016 Eleven Biotherapeutics Reports Second Quarter 2016 Financial Results and Provides Strategic Update View HTML
July 7, 2016 Eleven Biotherapeutics Announces Effectiveness of Investigational New Drug Application for EBI-031 View HTML
June 13, 2016 Eleven Biotherapeutics Announces Signing of Exclusive License Agreement View HTML
June 13, 2016 Eleven Biotherapeutics Announces Investigational New Drug Application Submission to Initiate Clinical Trials of EBI-031 for Ocular Diseases View HTML
May 5, 2016 Eleven Biotherapeutics Reports First Quarter 2016 Financial Results View HTML
April 29, 2016 Eleven Biotherapeutics to Present Data at the ARVO 2016 Annual Meeting View HTML